The Centers for Medicare and Medicaid Services (CMS) is currently considering an amendment proposal to the Massachusetts Medicaid (MassHealth) waiver. If approved, this waiver could have a significant impact on access to treatments, especially innovative medications, for those in Massachusetts Medicaid. This waiver has the potential to set a terrible precedent for Medicaid programs across the country.
The Epilepsy Foundation is particularly concerned about aspects of the proposal related to access to medications. One proposal would create a closed formulary that would ensure coverage of just one drug per class, while another proposal would limit access to innovative new therapies approved by the FDA via expedited pathways by subjecting some new medications to an additional review to further assess efficacy. These changes could limit affordable access to epilepsy medications, and risk the health of people with epilepsy who rely on Massachusetts Medicaid.
On August 21, 2017, the Epilepsy Foundation submitted comments to the state Department of Health and Human Services Office of Medicaid, expressing concerns with the proposed amendment. Read our letter below.
EF Comment - MA EOHHS 1115 Medicaid Waiver (August 21, 2017)
On October 18, 2017, the Epilepsy Foundation, and several of our local affiliates and chapters, joined comments to CMS, the federal agency who will ultimately approve or deny the waiver, by a group of 222 organizations that particularly highlighted concerns with the closed formulary aspect of the proposal. Read these comments below.
CMS Comment MassHealth 1115 patient groups sign-on letter (Oct 18 2017)